GAM Holding AG Grows Position in Johnson & Johnson (NYSE:JNJ)

Defense World · Apr 29, 2023 06:43

GAM Holding AG raised its holdings in shares of Johnson & Johnson (NYSE:JNJ – Get Rating) by 5.1% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 84,225 shares of the company's stock after purchasing an additional 4,065 shares during the quarter. Johnson & Johnson makes up approximately 1.2% of GAM Holding AG's portfolio, making the stock its 18th largest holding. GAM Holding AG's holdings in Johnson & Johnson were worth $14,878,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. Vanguard Group Inc. increased its position in shares of Johnson & Johnson by 1.2% during the third quarter. Vanguard Group Inc. now owns 245,340,875 shares of the company's stock valued at $40,078,885,000 after buying an additional 2,815,655 shares during the period. State Street Corp increased its position in shares of Johnson & Johnson by 0.6% during the third quarter. State Street Corp now owns 141,886,311 shares of the company's stock valued at $23,178,548,000 after buying an additional 803,013 shares during the period. Price T Rowe Associates Inc. MD increased its position in shares of Johnson & Johnson by 3.3% during the third quarter. Price T Rowe Associates Inc. MD now owns 25,428,626 shares of the company's stock valued at $4,154,022,000 after buying an additional 805,831 shares during the period. Charles Schwab Investment Management Inc. increased its position in shares of Johnson & Johnson by 1.9% during the first quarter. Charles Schwab Investment Management Inc. now owns 17,189,229 shares of the company's stock valued at $3,046,449,000 after buying an additional 328,297 shares during the period. Finally, California Public Employees Retirement System increased its position in shares of Johnson & Johnson by 2.7% during the third quarter. California Public Employees Retirement System now owns 11,751,504 shares of the company's stock valued at $1,919,726,000 after buying an additional 310,473 shares during the period. 67.94% of the stock is owned by hedge funds and other institutional investors.

Get Johnson & Johnson alerts:

Wall Street Analysts Forecast Growth

JNJ has been the topic of a number of recent analyst reports. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $215.00 target price on shares of Johnson & Johnson in a research note on Wednesday, February 1st. Guggenheim initiated coverage on shares of Johnson & Johnson in a research note on Tuesday, February 28th. They issued a "neutral" rating and a $161.00 target price on the stock. SVB Leerink lowered their target price on shares of Johnson & Johnson from $194.00 to $186.00 and set an "outperform" rating on the stock in a research note on Friday, January 20th. UBS Group initiated coverage on shares of Johnson & Johnson in a research note on Tuesday, March 28th. They issued a "neutral" rating and a $164.00 target price on the stock. Finally, Piper Sandler lowered their target price on shares of Johnson & Johnson from $55.00 to $52.00 in a research note on Monday, February 6th. Seven analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $173.00.

Insider Transactions at Johnson & Johnson

In related news, insider James D. Swanson sold 1,062 shares of Johnson & Johnson stock in a transaction on Monday, March 6th. The shares were sold at an average price of $154.66, for a total value of $164,248.92. Following the sale, the insider now owns 9,215 shares in the company, valued at $1,425,191.90. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 0.20% of the company's stock.

Johnson & Johnson Stock Up 0.4 %

Shares of Johnson & Johnson stock opened at $163.70 on Friday. The company has a debt-to-equity ratio of 0.35, a quick ratio of 0.77 and a current ratio of 0.99. Johnson & Johnson has a 52-week low of $150.11 and a 52-week high of $183.35. The stock has a market capitalization of $426.32 billion, a price-to-earnings ratio of 34.25, a P/E/G ratio of 2.77 and a beta of 0.53. The company's 50 day moving average price is $157.80 and its 200-day moving average price is $166.99.

Johnson & Johnson (NYSE:JNJ – Get Rating) last issued its earnings results on Tuesday, April 18th. The company reported $2.68 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.51 by $0.17. Johnson & Johnson had a net margin of 13.22% and a return on equity of 35.53%. The firm had revenue of $24.75 billion for the quarter, compared to analysts' expectations of $23.61 billion. During the same quarter last year, the business earned $2.67 earnings per share. The business's revenue was up 5.6% on a year-over-year basis. Equities research analysts forecast that Johnson & Johnson will post 10.67 EPS for the current year.

Johnson & Johnson Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 6th. Stockholders of record on Tuesday, May 23rd will be issued a $1.19 dividend. This is a boost from Johnson & Johnson's previous quarterly dividend of $1.13. The ex-dividend date is Monday, May 22nd. This represents a $4.76 annualized dividend and a dividend yield of 2.91%. Johnson & Johnson's dividend payout ratio (DPR) is currently 94.56%.

Johnson & Johnson Company Profile

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women's Health and Wound Care markets.